NeoImmuneTech, Inc. (KOSDAQ:950220)

South Korea · Delayed Price · Currency is KRW

1,577.00

+31.00 (2.01%)

Aug 12, 2026, 3:30 PM KST

-74.77% (1Y)

Market Cap	152.85B -75.3%
Revenue (ttm)	608.57M +231.4%
Net Income	-31.04B
EPS	-232.79
Shares Out	98.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	180,149
Open	1,551.00
Previous Close	1,546.00
Day's Range	1,490.00 - 1,617.00
52-Week Range	1,115.00 - 6,835.00
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About NeoImmuneTech

NeoImmuneTech, Inc., a clinical-stage T cell-based biotechnology company, develops and sells immuno-therapeutics in Korea. It is developing NT-I7, an IL-7 class T- cell amplifier to treat acute radiation syndrome; and Heterodimer hybrid Fc platform, an antibody platform technology, as well as NT2020, a T cell activator; NT3020, a T cell engager; NT4010, an advanced CAR-T; and NT5010, a TME modifier. The company was incorporated in 2014 and is headquartered in Rockville, Maryland. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Employees 52

Stock Exchange KOSDAQ

Ticker Symbol 950220

Full Company Profile

Financial Performance

In 2025, NeoImmuneTech's revenue was 94.82 million, a decrease of -44.35% compared to the previous year's 170.38 million. Losses were -31.80 billion, -22.23% less than in 2024.

Financial Statements